Xzid M 60mg/500mg Tablet ER

Metformin, a biguanide, improves insulin sensitivity by decreasing hepatic glucose production and enhancing peripheral glucose uptake. The extended-release formulation allows for a gradual release of active ingredients, promoting better glycemic control with reduced gastrointestinal side effects commonly associated with immediate-release metformin. Xzid M is typically administered once daily with meals to optimize absorption and minimize hypoglycemia risk.

Regular monitoring of blood glucose levels, renal function, and liver enzymes is recommended during therapy. Contraindications include type 1 diabetes, diabetic ketoacidosis, severe renal or hepatic impairment, and conditions predisposing to hypoxia. Caution is advised in patients with cardiovascular disease or elderly patients. This combination therapy offers a synergistic approach to glycemic management, improving patient compliance and therapeutic outcomes in type 2 diabetes mellitus.